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is an increasing problem with the aged population. In a
multicenter study, Hvass and associates18 found 171 (30%)
of 561 patients with a small aortic root as defined by a 19-
to 21-mm aortic annulus. In patients older than 80 years of
age, the percentage reached 40%.
A protocol testing hemodynamics over a wide range of
cardiac output allows a better evaluation of valve perfor-
mance when compared with most clinical studies perform-
ing echocardiographic evaluation at rest only. Moreover,
most of these echocardiographic studies do not mention the
cardiac output value at the time of the examination.10,11,13-15
This lack makes any comparison difficult because mean
transvalvular gradient, maximal transvalvular gradient, and
valve orifice area have all been demonstrated to be flow
dependent.19-21
A comparative study was designed because absolute
values found in the experimental setting cannot be extrap-
olated directly to human subjects, mainly because of ana-
tomic differences. For instance, in this study maximal trans-
valvular gradients have been found to be disproportionately
high in comparison with mean transvalvular gradients. This
is likely because of the particularly thickened aortic wall of
the calf, which offers a low compliant outflow chamber to
transvalvular blood flow.
As for limitations, this acute experimental model does
not evaluate the long-term outcome of prosthetic valves,
namely degeneration and durability. The theoretical reduc-
tion in leaflet stress leading to improved durability remains
a challenging issue that needs further evaluation. Second,
the sinotubular junction size in human subjects might be
larger than that of the annulus. In the Toronto valve expe-
rience, David22 recommended that the prosthesis should be
sized at the sinotubular junction. This usually leads to an
oversizing of the prosthesis when referred to the annulus.
The problem of 3F valve sizing deserves further evaluation.
Finally, candidates for aortic valve replacement might ex-
hibit a dilative tendency at the level of the sinotubular
junction, which might develop over time. This issue has
been shown to have relevant consequences in terms of late
prosthetic regurgitation.23 Whether the recommendation of
banding the sinotubular junction at the time of Toronto SPV
valve implantation should be applied to the 3F valve needs
to be evaluated.
We thank Philippe Frascarolo, PhD, for his help in the statis-
tical evaluation of this article.
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Discussion
Dr Henry M. Spotnitz (New York, NY). There are other issues
about valve design that you did not address in your presentation.
Can you tell us how the pericardium was preserved if at all,
whether you have any information about long-term durability,
issues of valvular regurgitation, and how critical you consider the
fixation of those tags to the aortic wall? Is that a critical issue, or
can they be sewn anyplace? Does it affect the amount of regurgi-
tation? What else can you tell us about that?
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Dr Mueller. I will start first with the last question. The very
critical point, as for the other stentless valve, is the anchoring of
these 3 points. They have to be very precisely positioned. They
should be fixed at about the level of the sinotubular junction or just
below it. If you do not fix them properly, and if the tubular form is not
achieved properly—you should have enough tension between the
inflow of the valve and the outflow—you will not achieve such a
gradient.
Fixation is standard low-pressure glutaraldehyde fixation.
Long-term durability has been tested in vitro according to the
ISO standards, and no specific defect has been noted.
Dr Wolfgang Goetz (Regensburg, Germany). This valve looks
very nice in the normal aortic root, but what if this root is dilated?
I would expect some tethering on the commissures, which are fixed
on only 3 points, and if there is a dilatation, I would expect some
central regurgitation.
Dr Mueller. Of course. This point has been raised recently
with the Toronto valve by Tirone David. His group observed some
aortic regurgitation with dilatation of the sinotubular junction, and
they suggested wrapping this area with a tape to fix it or to reduce
it. The present experimental study did not address this point, but
this finding should be valid for this stentless valve as well.
Dr Goetz. In contrast to a stentless valve, the commissures are
fixed on only one point. Therefore, if there is any kind of dilata-
tion, you might have a huge tethering there, and it might rupture at
these commissures.
Dr Mueller. There are 2 possibilities to address this problem.
First, you might oversize the valve. Second, you might reduce the
sinotubular junction, fix it, or both. This is obviously an important
point.
Dr Jose´ M. Revuelta (Santander, Spain). We just started using
this valve in our institution as part of an international multicenter
study, and we found it easy to implant. It is critical to produce a
good attachment at the top.
Concerning the previous question, if the aorta is dilated and the
patient has a dilated aorta, we need to remodel the sinotubular
junction. I think that this is not a contraindication.
My question is this: Did you use, in your clinical case, Prolene
running sutures or interrupted sutures? We prefer 4-0 Ethibond
interrupted sutures because it is only a 1-line suture. If something
happened, the patient would have a serious problem, particularly
with a fragile and calcified annulus, as is true in most of the cases.
Dr Mueller. We used interrupted sutures in the clinical case. In
the experimental setting we did the same because of the small size
of the annulus and because we did not want to have any purse-
string effect.
Dr Juan Carlos Chachques (Paris, France). First, I want to
ask why you use equine pericardium. There are some differences
with bovine histologically, because I think it would be more
difficult to use this material. Second, you are cutting 3 pieces of
your valve, but you make a tube. Why don’t you make only one
suture instead of taking 3 parts to make your valve?
Dr Mueller. In answer to the first question, equine pericardium
is thinner and more pliable. That was the idea behind that. Now,
for the tubular structure, if you take 3 equal pieces of pericardium
that are sutured together, you will already put the final form in line
when the distal end of the 3 linear sutures are fixed directly to the
aorta. In this way you obtain spontaneously a trileaflet structure
once it is closed by the backflow.
Dr Eugene A. Grossi (New York, NY). I enjoyed the presen-
tation. I especially enjoyed the picture of the Hegar dilators in
showing the difference in internal diameters of the valve.
Are you postulating that there is a difference in hemodynamic
performance because one valve has an internal diameter of 17 mm
versus a 19-mm internal diameter?
What is the method of sizing the valves? Because different
manufacturers use various methods for determining a particular
size, can this account for the hemodynamic differences, or do you
believe there are intrinsic differences in the valvular function other
than size?
Dr Mueller. Yes, the size was one of the main issues, espe-
cially with the Toronto valve, which has been recently compared
with the Carpentier-Edwards valve in that respect. With the 3F
valve, the 19-mm size corresponds to the inner diameter. With the
19-mm Hegar dilator, the outer diameter of the 3F valve is 20 mm.
Therefore, the wall of this valve is very thin.
The effect of the size characteristics of the valve on the hemo-
dynamics is definitely important, particularly for a small-sized
valve at low cardiac output. At higher output, you might expect
that the flow will push all the structures toward the recipient aortic
wall, but at lower output, these structures might partly obstruct the
outflow tract, especially with a small-sized valve.
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